Large-Scale Human Dendritic Cell Differentiation Revealing Notch-Dependent Lineage Bifurcation and Heterogeneity

Sreekumar Balan, Catharina Arnold-Schrauf, Abdenour Abbas, Norbert Couespel, Juliette Savoret, Francesco Imperatore, Alexandra-Chloé Villani, Thien-Phong Vu Manh, Nina Bhardwaj, Marc Dalod, Sreekumar Balan, Catharina Arnold-Schrauf, Abdenour Abbas, Norbert Couespel, Juliette Savoret, Francesco Imperatore, Alexandra-Chloé Villani, Thien-Phong Vu Manh, Nina Bhardwaj, Marc Dalod

Abstract

The ability to generate large numbers of distinct types of human dendritic cells (DCs) in vitro is critical for accelerating our understanding of DC biology and harnessing them clinically. We developed a DC differentiation method from human CD34+ precursors leading to high yields of plasmacytoid DCs (pDCs) and both types of conventional DCs (cDC1s and cDC2s). The identity of the cells generated in vitro and their strong homology to their blood counterparts were demonstrated by phenotypic, functional, and single-cell RNA-sequencing analyses. This culture system revealed a critical role of Notch signaling and GM-CSF for promoting cDC1 generation. Moreover, we discovered a pre-terminal differentiation state for each DC type, characterized by high expression of cell-cycle genes and lack of XCR1 in the case of cDC1. Our culture system will greatly facilitate the simultaneous and comprehensive study of primary, otherwise rare human DC types, including their mutual interactions.

Keywords: CLEC10A; CLEC9A; NOTCH; XCR1; adjuvant; dendritic cell differentiation; dendritic cell types; hematopoiesis; immunotherapy; plasmacytoid dendritic cells.

Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
pDCs and cDC1s Can Be Efficiently Generated from Human CD34+ Cord Blood Cells (A) CD34+ cord blood (CB) cells were expanded with FLT3L, SCF, TPO, and IL-7 (FST7) for 7 days. Subsequently, they were differentiated on OP9, OP9_DLL1, or OP9+OP9_DLL1 feeder layer cells, with FLT3L, TPO, and IL-7 (FT7), for 14–21 days. (B) On day 18 of differentiation, within the live-cell gate, pDCs were identified as CD206−CD14−CD123+BDCA2+ cells and cDC1s as CD206−CD14−CLEC9A+ cells positive for BDCA3 or CADM1. Plots show one experiment using CB204 donor CD34+ cells for parallel differentiation on the 3 feeder layers. Data are representative of 5 experiments each performed with cells from one or two different donors. Pie charts show mean percentage of pDCs or cDC1s within the live-cell gate from the 5 experiments. (C and D) Frequencies (C) and numbers per well (i.e., per 104 expanded CD34+ cells) (D) of cDC1s (top) and pDCs (bottom) among total live cells on day 18 after differentiation on the 3 different feeder layers. Graphs show individual results for each of the 6 donors. See also Figures S1 and S2 and Table S1.
Figure 2
Figure 2
cDC1s Develop from Human CD34+ CB Cells Dependent on Notch Signaling (A) Expanded CD34+ CB cells were differentiated with FT7 on OP9_DLL1 feeder layer cells in the presence or absence of DAPT or DMSO. (B) Plots show one experiment using CB204 donor CD34+ cells. Data are representative of 5 experiments each performed with cells from 1–3 different donors. Pie charts show mean percentage of pDCs or cDC1s within the live-cell gate from the 8 donors on day 18–21 of differentiation. (C and D) Frequency (C) and numbers per well (D) of cDC1s (top) and pDCs (bottom) among total live cells. Graphs show individual results for each of the 8 donors.
Figure 3
Figure 3
Notch Signaling Impacts cDC1 Differentiation from Human CD34+ CB Cells Early During Development (A) Experimental setup. Medium (untreated), DAPT, or DMSO was added on one or several days during differentiation to define when DAPT inhibits cDC1 development. (B) Frequency of cDC1s (left) and pDCs (right) among total live cells after DMSO or DAPT treatment. Data from triplicate wells of one donor representative of 5 tested are depicted. (C) Numbers of live cDC1s (left) and pDCs (right) after DMSO or DAPT treatment. Numbers are normalized to DMSO and represent mean values of triplicate wells for 3 donors from one experiment representative of two. The mean ± SD across the three donors is shown for each experimental condition. Statistics were performed using the Student’s paired t test.
Figure 4
Figure 4
pDCs and cDC1s Generated from Human CD34+ CB Cells Share Key Functional Characteristics with Their Blood Counterparts OP9+OP9_DLL1 FT7 cultures were stimulated with the indicated agonists. cDC1s were gated as live CD14−CD206−CD123neg-to-lowBDCA2−CADM1+ cells and pDCs as CD14−CD206−CD123+BDCA2+ cells. Plots are representative of 4 donors from 2 experiments. (A) Activation marker expression. (B) Intracellular expression of IFN-α/λ. (C) Intracellular expression of IL-12p40 and TNF.
Figure 5
Figure 5
Flow Cytometric and scRNAseq Analyses Confirm the Identity of the pDCs and cDC1s Generated from Human CD34+ CB Cells and Identify Heterogeneity within cDC1s (A) viSNE plots from live Lin−HLA-DR+ cells harvested from 18 day OP9+OP9_DLL1 FT7 cultures. Color codes indicate relative levels of marker cell-surface expression. (B) Overlay of the viSNE plot shown in (A) with the manually gated populations indicated in the legend. pDCs were gated as BDCA2+CD123+ and cDC1s as BDCA2−CD123neg-to-lowCADM1+CD1c+. In the remaining CADM1− cells, CD1c+ cells were subdivided into BTLA−CX3CR1+ and BTLA+ cells. Plots are representative of 4 donors from 2 experiments. (C) Lineage−HLA-DR+ single cells were index sorted for phenotypes of cDC1s (CD141+CADM1+), pDCs (CADM1−CD123+BDCA2+), putative pre-cDC2s (CADM1−BDCA2−CD1c+BTLA+), or putative cDC2s (CADM1−BDCA2−CD1c+BTLA−), as indicated by the symbols in the graphical legend. scRNAseq was performed using the SmartSeq2 protocol, followed by unsupervised dimensional reduction of the data using t-distributed stochastic neighbor embedding (t-SNE) with graph-based clustering. 7 cell clusters were identified as indicated by the color code in the graphical legend. (D) Violin plots showing mRNA expression profiles of previously known MNP-type-specific genes across all individual cells and in comparison between clusters identified in (A). (E) Enrichment analyses performed on each cell using connectivity map (cMAP), with independently generated and previously published human MNP-type-specific transcriptomic fingerprints. Results are presented as violin plots showing cell densities for the different cMAP scores (y axis) across the cell clusters (x axis) identified in (A). cMAP scores close to 1 versus −1 indicate strong enrichment of the signature of the cell type labeled on top versus bottom of the y axis. (F) Violin plots showing expression profiles of differentially expressed genes between clusters 6 and 7 (cDC1s). Individual dots represent single cells (C, D, and F). Data in (C)–(F) represent one experiment using one donor. (G) Protein expression of CLEC9A and CXCR4 on Lin−HLA-DR+CADM1+BDCA2−XCR1− and XCR1+ cDC1s from FT7 cultures analyzed by flow cytometry. Plots are representative of 3 experiments and 5 donors. (H) Protein expression of CLEC9A and XCR1 on Lin−HLA-DR+CD11c+ CD1c−CADM1+ cDC1s from adult peripheral blood analyzed by flow cytometry. Plots are representative of 3 experiments encompassing 6 different donors. (I) XCR1 protein expression on adult peripheral blood cDC1s sorted as Lin−HLA-DR+CD11c+CD1c−CD141+CADM1+CLEC9A+ and either XCR1+ or XCR1− 14 days after in vitro culture on OP9-DLL1 cells with the FT7+G cytokine cocktail. One experiment representative of three is shown. Dotted line, fluorescent minus one control; plain line, XCR1 staining. (J) Expansion of the sorted XCR1− subset of adult peripheral blood cDC1s after 14 days of in vitro culture on OP9-DLL1 cells with the FT7 cytokine cocktail supplemented with GM-CSF (1 ng/mL). Data shown are from 3 experiments, each with a different donor (symbols), with mean ± Sd shown across the three donors for each experimental condition. See also Figures S3–S6 and Data S1.
Figure 6
Figure 6
GM-CSF Promotes cDC1 Differentiation from CB and Non-mobilized Adult Blood CD34+ Cells (A–C) Expanded CD34+ CB cells were differentiated with FT7 on OP9_DLL1 feeder layer cells in the absence or presence of GM-CSF added at different time points. (A) Top: frequencies of live CD123+ and CD141+ cells in the CD14−CD206− gate. Bottom: frequencies of CD141+CLEC9A− and CD141+CLEC9A+ cells within the CD141+ gate shown on the top. Plots are from one donor (representative of 4). FT7+G, 1 ng/mL GM-CSF added to FT7 on days 0, 7, and 14 of differentiation. (B and C) Frequencies (top) and absolute numbers (bottom) of cDC1s (B) and pDCs (C) generated in the absence or presence of GM-CSF added at the indicated concentrations on days 0, 7, and 14 (w1–3), 7 and 14 (w2–3), or 14 (w3) of differentiation. Absolute numbers of cells obtained were calculated for an initial input of 104 CD34+ CB cells, taking into consideration both the expansion and differentiation phases. Data shown are from 4 experiments, each with a different donor (symbols), with mean ± SD shown across donors for each experimental condition. Statistics were performed comparing each condition of GM-CSF supplementation with the FT7 control culture. (D) Carboxyfluorescein diacetate succinimidyl ester (CFSE)-stained cells were differentiated with FT7 or FT7+G (0.25 ng/mL) and harvested over time to measure cell expansion. Each symbol represents an individual donor (D1, D2, and D3). The open versus closed formats represent different days of harvest (day [d]6, d12, and d18). (E) Mean CFSE fluorescent intensity at days 6 and 12 on total cells in the same differentiation cultures as shown in (D). (F) Fraction of live (PI−Annexin-V−) versus early apoptotic (PI−Annexin-V+), late apoptotic (PI+Annexin-V+), or necrotic (PI+Annexin-V−/low) cells in cultures over time, for the individual donors (symbols), which mean ±SD shown across donors for each day. (G) Frequency of XCR1− versus XCR1+ cells in the cDC1s generated in vitro from FST7-expanded CB CD34+ cells differentiated for 18 days on OP9_DLL1 feeders with FT7 or FT7+G. Data shown are from 2 experiments, each with 1–3 different donors (symbols), with mean ± SD shown across donors for each experimental condition. (H) Frequency (top) and total numbers (bottom) of CD123+CD45RA+ pDCs and CD141+CLEC9A+ cDC1s generated from 104 non-mobilized FST7-expanded CD34+ cell from adult peripheral blood differentiated on OP9+OP9_DLL1 feeder with FT7 or FT7+G. Data shown are from 3 experiments, each with 2 different donors (6 data points with their mena ± SD shown for each condition).
Figure 7
Figure 7
Unbiased Analysis of the Composition of OP9+OP9_DLL1 FT7 Cultures through Droplet-Based High-Throughput scRNAseq (A) scRNAseq-based identification of clusters of cell types or states from viable CD45+ cells from one culture using t-SNE with graphical clustering. 12 cell clusters were identified. The numbers of cells in each cluster are indicated in the graphical legend box, together with the percentages they represent out of the total cells analyzed. (B) Violin plots showing expression profiles of previously known cell-type-specific genes across all individual cells and in comparison between cell clusters. (C) Identification of clusters of cell types or states from sorted Lineage−HLA-DR+ cells. 13 cell clusters were identified. (D) Violin plots showing expression profiles of the same genes as in (B). (E and F) Expression patterns of 156 genes representative of those that were the most differentially expressed across cell clusters, as a heatmap with hierarchical clustering of cell clusters (columns) and genes (rows), for total live CD45+ cells (E) and enriched Lineage−HLA-DR+ cells (F). Genes clustered largely according to previously known co-expression in specific cell types, as highlighted by the vertical bars and their annotations on the right of each heatmap. See also Figure S7 and Data S1.

References

    1. Adema G.J., de Vries I.J., Punt C.J., Figdor C.G. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr. Opin. Immunol. 2005;17:170–174.
    1. Amir el A.D., Davis K.L., Tadmor M.D., Simonds E.F., Levine J.H., Bendall S.C., Shenfeld D.K., Krishnaswamy S., Nolan G.P., Pe’er D. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat. Biotechnol. 2013;31:545–552.
    1. Anders S., Pyl P.T., Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166–169.
    1. Bachem A., Hartung E., Güttler S., Mora A., Zhou X., Hegemann A., Plantinga M., Mazzini E., Stoitzner P., Gurka S. Expression of XCR1 characterizes the Batf3-dependent lineage of dendritic cells capable of antigen cross-presentation. Front. Immunol. 2012;3:214.
    1. Bakdash G., Buschow S.I., Gorris M.A., Halilovic A., Hato S.V., Sköld A.E., Schreibelt G., Sittig S.P., Torensma R., Duiveman-de Boer T. Expansion of a BDCA1+CD14+ myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines. Cancer Res. 2016;76:4332–4346.
    1. Balan S., Ollion V., Colletti N., Chelbi R., Montanana-Sanchis F., Liu H., Vu Manh T.P., Sanchez C., Savoret J., Perrot I. Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells. J. Immunol. 2014;193:1622–1635.
    1. Bol K.F., Tel J., de Vries I.J., Figdor C.G. Naturally circulating dendritic cells to vaccinate cancer patients. OncoImmunology. 2013;2:e23431.
    1. Breton G., Lee J., Zhou Y.J., Schreiber J.J., Keler T., Puhr S., Anandasabapathy N., Schlesinger S., Caskey M., Liu K., Nussenzweig M.C. Circulating precursors of human CD1c+ and CD141+ dendritic cells. J. Exp. Med. 2015;212:401–413.
    1. Breton G., Zheng S., Valieris R., Tojal da Silva I., Satija R., Nussenzweig M.C. Human dendritic cells (DCs) are derived from distinct circulating precursors that are precommitted to become CD1c+ or CD141+ DCs. J. Exp. Med. 2016;213:2861–2870.
    1. Cao W., Zhang L., Rosen D.B., Bover L., Watanabe G., Bao M., Lanier L.L., Liu Y.J. BDCA2/Fc epsilon RI gamma complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells. PLoS Biol. 2007;5:e248.
    1. Carpentier S., Vu Manh T.P., Chelbi R., Henri S., Malissen B., Haniffa M., Ginhoux F., Dalod M. Comparative genomics analysis of mononuclear phagocyte subsets confirms homology between lymphoid tissue-resident and dermal XCR1(+) DCs in mouse and human and distinguishes them from Langerhans cells. J. Immunol. Methods. 2016;432:35–49.
    1. Dobin A., Davis C.A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T.R. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.
    1. Dontje W., Schotte R., Cupedo T., Nagasawa M., Scheeren F., Gimeno R., Spits H., Blom B. Delta-like1-induced Notch1 signaling regulates the human plasmacytoid dendritic cell versus T-cell lineage decision through control of GATA-3 and Spi-B. Blood. 2006;107:2446–2452.
    1. Dresch C., Leverrier Y., Marvel J., Shortman K. Development of antigen cross-presentation capacity in dendritic cells. Trends Immunol. 2012;33:381–388.
    1. Ghosh H.S., Cisse B., Bunin A., Lewis K.L., Reizis B. Continuous expression of the transcription factor e2-2 maintains the cell fate of mature plasmacytoid dendritic cells. Immunity. 2010;33:905–916.
    1. Haniffa M., Shin A., Bigley V., McGovern N., Teo P., See P., Wasan P.S., Wang X.N., Malinarich F., Malleret B. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity. 2012;37:60–73.
    1. Heidkamp G.F., Sander J., Lehmann C.H.K., Heger L., Eissing N., Baranska A., Lühr J.J., Hoffmann A., Reimer K.C., Lux A. Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment. Sci. Immunol. 2016;1:eaai7677.
    1. Hémont C., Neel A., Heslan M., Braudeau C., Josien R. Human blood mDC subsets exhibit distinct TLR repertoire and responsiveness. J. Leukoc. Biol. 2013;93:599–609.
    1. Ito T., Kanzler H., Duramad O., Cao W., Liu Y.J. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood. 2006;107:2423–2431.
    1. James B.R., Brincks E.L., Kucaba T.A., Boon L., Griffith T.S. Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells. Cancer Immunol. Immunother. 2014;63:685–697.
    1. Jongbloed S.L., Kassianos A.J., McDonald K.J., Clark G.J., Ju X., Angel C.E., Chen C.J., Dunbar P.R., Wadley R.B., Jeet V. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 2010;207:1247–1260.
    1. Kirkling M.E., Cytlak U., Lau C.M., Lewis K.L., Resteu A., Khodadadi-Jamayran A., Siebel C.W., Salmon H., Merad M., Tsirigos A. Notch signaling facilitates in vitro generation of cross-presenting classical dendritic cells. Cell Rep. 2018;23:3658–3672.e3656.
    1. Kodama H., Nose M., Niida S., Nishikawa S., Nishikawa S. Involvement of the c-kit receptor in the adhesion of hematopoietic stem cells to stromal cells. Exp. Hematol. 1994;22:979–984.
    1. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J., Brunet J.P., Subramanian A., Ross K.N. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929–1935.
    1. Lauterbach H., Bathke B., Gilles S., Traidl-Hoffmann C., Luber C.A., Fejer G., Freudenberg M.A., Davey G.M., Vremec D., Kallies A. Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J. Exp. Med. 2010;207:2703–2717.
    1. Lee J., Breton G., Oliveira T.Y., Zhou Y.J., Aljoufi A., Puhr S., Cameron M.J., Sékaly R.P., Nussenzweig M.C., Liu K. Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow. J. Exp. Med. 2015;212:385–399.
    1. Lewis K.L., Caton M.L., Bogunovic M., Greter M., Grajkowska L.T., Ng D., Klinakis A., Charo I.F., Jung S., Gommerman J.L. Notch2 receptor signaling controls functional differentiation of dendritic cells in the spleen and intestine. Immunity. 2011;35:780–791.
    1. Mabbott N.A., Baillie J.K., Brown H., Freeman T.C., Hume D.A. An expression atlas of human primary cells: inference of gene function from coexpression networks. BMC Genomics. 2013;14:632.
    1. Maraskovsky E., Brasel K., Teepe M., Roux E.R., Lyman S.D., Shortman K., McKenna H.J. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 1996;184:1953–1962.
    1. Martín-Gayo E., González-García S., García-León M.J., Murcia-Ceballos A., Alcain J., García-Peydró M., Allende L., de Andrés B., Gaspar M.L., Toribio M.L. Spatially restricted JAG1-Notch signaling in human thymus provides suitable DC developmental niches. J. Exp. Med. 2017;214:3361–3379.
    1. Meixlsperger S., Leung C.S., Rämer P.C., Pack M., Vanoaica L.D., Breton G., Pascolo S., Salazar A.M., Dzionek A., Schmitz J. CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood. 2013;121:5034–5044.
    1. Moreau A., Alliot-Licht B., Cuturi M.C., Blancho G. Tolerogenic dendritic cell therapy in organ transplantation. Transpl. Int. 2017;30:754–764.
    1. Nierkens S., den Brok M.H., Garcia Z., Togher S., Wagenaars J., Wassink M., Boon L., Ruers T.J., Figdor C.G., Schoenberger S.P. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res. 2011;71:6428–6437.
    1. Olivier A., Lauret E., Gonin P., Galy A. The Notch ligand delta-1 is a hematopoietic development cofactor for plasmacytoid dendritic cells. Blood. 2006;107:2694–2701.
    1. Plantinga M., Guilliams M., Vanheerswynghels M., Deswarte K., Branco-Madeira F., Toussaint W., Vanhoutte L., Neyt K., Killeen N., Malissen B. Conventional and monocyte-derived CD11b(+) dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen. Immunity. 2013;38:322–335.
    1. Robbins S.H., Walzer T., Dembélé D., Thibault C., Defays A., Bessou G., Xu H., Vivier E., Sellars M., Pierre P. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol. 2008;9:R17.
    1. Sabado R.L., Balan S., Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27:74–95.
    1. Sathe P., Vremec D., Wu L., Corcoran L., Shortman K. Convergent differentiation: myeloid and lymphoid pathways to murine plasmacytoid dendritic cells. Blood. 2013;121:11–19.
    1. Satija R., Farrell J.A., Gennert D., Schier A.F., Regev A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 2015;33:495–502.
    1. Saxena M., Balan S., Roudko V., Bhardwaj N. Towards superior dendritic-cell vaccines for cancer therapy. Nat. Biomed. Eng. 2018;2:341–346.
    1. Schlitzer A., Sivakamasundari V., Chen J., Sumatoh H.R., Schreuder J., Lum J., Malleret B., Zhang S., Larbi A., Zolezzi F. Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow. Nat. Immunol. 2015;16:718–728.
    1. Schmitt T.M., de Pooter R.F., Gronski M.A., Cho S.K., Ohashi P.S., Zúñiga-Pflücker J.C. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat. Immunol. 2004;5:410–417.
    1. See P., Dutertre C.A., Chen J., Günther P., McGovern N., Irac S.E., Gunawan M., Beyer M., Händler K., Duan K. Mapping the human DC lineage through the integration of high-dimensional techniques. Science. 2017;356:356.
    1. Sluijter B.J., van den Hout M.F., Koster B.D., van Leeuwen P.A., Schneiders F.L., van de Ven R., Molenkamp B.G., Vosslamber S., Verweij C.L., van den Tol M.P. Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: recruitment and activation of BDCA3/CD141(+) dendritic cells and enhanced cross-presentation. Cancer Immunol. Res. 2015;3:495–505.
    1. Spinelli L., Carpentier S., Montañana Sanchis F., Dalod M., Vu Manh T.P. BubbleGUM: automatic extraction of phenotype molecular signatures and comprehensive visualization of multiple Gene Set Enrichment Analyses. BMC Genomics. 2015;16:814.
    1. Tel J., Aarntzen E.H., Baba T., Schreibelt G., Schulte B.M., Benitez-Ribas D., Boerman O.C., Croockewit S., Oyen W.J., van Rossum M. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 2013;73:1063–1075.
    1. Thordardottir S., Hangalapura B.N., Hutten T., Cossu M., Spanholtz J., Schaap N., Radstake T.R., van der Voort R., Dolstra H. The aryl hydrocarbon receptor antagonist StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34+ hematopoietic progenitor cells. Stem Cells Dev. 2014;23:955–967.
    1. Tomasello E., Pollet E., Vu Manh T.P., Uzé G., Dalod M. Harnessing mechanistic knowledge on beneficial versus deleterious IFN-I effects to design innovative immunotherapies targeting cytokine activity to specific cell types. Front. Immunol. 2014;5:526.
    1. Trapnell C. Defining cell types and states with single-cell genomics. Genome Res. 2015;25:1491–1498.
    1. Villani A.C., Satija R., Reynolds G., Sarkizova S., Shekhar K., Fletcher J., Griesbeck M., Butler A., Zheng S., Lazo S. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356:eaah4573.
    1. Vu Manh T.P., Bertho N., Hosmalin A., Schwartz-Cornil I., Dalod M. Investigating evolutionary conservation of dendritic cell subset identity and functions. Front. Immunol. 2015;6:260.
    1. Vu Manh T.P., Elhmouzi-Younes J., Urien C., Ruscanu S., Jouneau L., Bourge M., Moroldo M., Foucras G., Salmon H., Marty H. Defining mononuclear phagocyte subset homology across several distant warm-blooded vertebrates through comparative transcriptomics. Front. Immunol. 2015;6:299.
    1. Zhang Y., Chen G., Liu Z., Tian S., Zhang J., Carey C.D., Murphy K.M., Storkus W.J., Falo L.D., Jr., You Z. Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity. J. Immunol. 2015;194:5937–5947.
    1. Ziegler-Heitbrock L., Ancuta P., Crowe S., Dalod M., Grau V., Hart D.N., Leenen P.J., Liu Y.J., MacPherson G., Randolph G.J. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116:e74–e80.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する